ARTICLE | Clinical News
FDA accepts Icon's NDA for ophthalmic product Dexycu
August 18, 2017 4:30 PM UTC
In June, Icon Bioscience Inc. (Newark, Calif.) said FDA accepted for review an NDA for Dexycu (IBI-10090) to reduce inflammation after cataract surgery. Its PDUFA date is Feb. 12, 2018. The company e...
BCIQ Company Profiles